Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.
KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. The company's mission is to bring innovative treatments to patients suffering from a range of diseases, with a strong focus on hereditary angioedema (HAE) and diabetic macular edema (DME).
KalVista's core business revolves around developing small molecule plasma kallikrein inhibitors. Their product portfolio includes:
- Hereditary Angioedema (HAE) inhibitors: These inhibitors are designed to prevent and treat the debilitating attacks associated with HAE, a disorder characterized by severe swelling in various body parts.
- Diabetic Macular Edema (DME) inhibitors: These inhibitors target plasma kallikrein, which is implicated in the retinal vascular permeability that leads to DME, a common complication of diabetes that can cause vision loss.
The company operates primarily in the United States and has made significant strides in its research and development efforts. Recent achievements include successful clinical trials, strategic partnerships, and securing funding to advance their pipeline projects.
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments. The company prioritizes transparency and regularly updates stakeholders on its progress through press releases and public disclosures.
Investors looking to keep abreast of the latest developments and financial performance of KalVista Pharmaceuticals can find comprehensive updates and reports on their official website and through stock market platforms like StockTitan.
KalVista Pharmaceuticals announced that data from the phase 3 KONFIDENT trial of sebetralstat, an oral treatment for hereditary angioedema (HAE), was published in the New England Journal of Medicine and presented at the European Academy of Allergy and Clinical Immunology Congress 2024.
The trial met its primary and secondary endpoints, with a median symptom relief time of 1.61 hours for 300 mg and 1.79 hours for 600 mg doses, compared to 6.72 hours for placebo. The safety profile was comparable to placebo, with low adverse event rates.
In the KONFIDENT-S open-label trial, sebetralstat showed a median treatment time of 9 minutes and a median symptom relief time of 1.8 hours, with consistent efficacy across various attack severities and locations.
KalVista plans to submit a new drug application to the US FDA in June 2024, and later in the EU and Japan.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the acceptance of ten abstracts for presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 in Valencia, Spain, from May 31 to June 3. Highlights include late-breaking presentations on the phase 3 KONFIDENT and KONFIDENT-S trials of sebetralstat, an oral treatment for hereditary angioedema (HAE), and multiple real-world data presentations addressing delays in injectable on-demand treatments for HAE. Key sessions are scheduled throughout the event, including oral abstracts, poster presentations, and symposiums focusing on various aspects of HAE treatment and patient experiences.
KalVista Pharmaceuticals, a clinical-stage pharmaceutical company focusing on oral, small molecule protease inhibitors, announced participation in two upcoming investor conferences. The management will join a virtual fireside chat at the Stifel 2024 Tailoring Genes: Genetic Medicines Forum on May 28, 2024, at 12:50 p.m. ET, and the Jefferies Global Healthcare Conference in New York on June 5, 2024, at 3:00 p.m. ET. The presentations will be webcasted live, with an audio archive available on the company's website for 30 days post-event.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) granted ten newly-hired employees inducement options to purchase 94,000 shares of common stock on May 1, 2024. The options have an exercise price of $12.18 per share and vest over a four-year period. This action was taken in accordance with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its strategic plans for fiscal year 2025, focusing on sebetralstat, an oral therapy for hereditary angioedema. The company aims to finalize regulatory filings in the US, EU, UK, and Japan for potential commercial launches in 2025-2026. KalVista plans to engage commercial partners, extend the product lifecycle, and reduce spending on non-core activities to achieve positive cash flow within a few years of commercial launch.
FAQ
What is the current stock price of KalVista Pharmaceuticals (KALV)?
What is the market cap of KalVista Pharmaceuticals (KALV)?
What does KalVista Pharmaceuticals specialize in?
What diseases does KalVista target with its products?
What is a plasma kallikrein inhibitor?
Where does KalVista Pharmaceuticals operate?
How can investors stay updated on KalVista's progress?
Has KalVista formed any strategic partnerships?
What are KalVista's recent achievements?
What is hereditary angioedema (HAE)?
What is diabetic macular edema (DME)?
What financial condition is KalVista in?
